Enara Bio
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Robert Robinson Ave, Oxford, Oxfordshi...Website
www.enarabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Enara Bio
Enara Bio is a biopharmaceutical company focused on advancing cancer immunotherapy by discovering and developing novel Dark Antigens and bispecific T-cell engagers for solid tumors. Their mission is to exploit genomic dark matter to create transformative cancer treatments for broad patient populations. The company has developed innovative technology platforms, including EDAPT and EnTiCE, to optimize their proprietary therapies. Enara Bio aims to make a significant impact in the field of oncology, with a diverse and experienced team dedicated to their vision.Explore more
Enara Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enara Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Enara Bio has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Enara Bio launches new products
Enara Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Enara Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Enara Bio had a recent Job posting/layoffs
Check out if Enara Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Enara Bio
Earning: See what the market has to say on Enara Bio recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Enara Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to Enara Bio
Compare insights from companies similar to Enara Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Enara Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Enara Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Enara Bio.
Enara Bio financials insights
Gather financial insights about Enara Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$17.5M
2024
Series B
$32.5M
Enara Bio Tech Stack
A closer look at the technologies used by Enara Bio
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Enara Bio News & Media
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
Oxford, UK – March 17, 2026. Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead clinical candidate, ENA101, a first-in-class bispecific T cell engager (TCE) targeting DARKFOX®, a novel cancer-specific Dark Antigen discovered with Enara’s EDAPT® platform.Enara Bio Enters 2026 with Dark Antigen Licensing to Boehringer Ingelheim, Appointment of Chief Medical Officer and Plans to Advance DARKFOX T-cell Engager into First-in-Human Studies
Oxford, UK – January 8, 2026. Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T-cell engagers for solid tumors, today announced that Boehringer Ingelheim has exercised its option to license multiple additional Dark Antigen targets discovered and validated through the collaboration with Enara.Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies
Oxford, United Kingdom – November 4, 2025. Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumors, will unveil its newly discovered cancer-specific target DARKFOXTM as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in NationalEnara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
Oxford, United Kingdom – October 3, 2025. Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumors, will present two abstracts related to the significant therapeutic potential of DARKFOXTM at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Enara Bio
Sign Up For FreeTo access detailed company insights
Enara Bio is a biopharmaceutical company focused on advancing cancer immunotherapy by discovering and developing novel Dark Antigens and bispecific T-cell engagers for solid tumors. Their mission is to exploit genomic dark matter to create transformative cancer treatments for broad patient populations. The company has developed innovative technolog... Read More
